Skip to content
mapperlab
← Dashboard
Stock

RVMD

Revolution Medicines, Inc.
Latest close $1447 of 27 marquee funds currently hold2 CUSIPs mapped
Current holders
7
27 funds tracked
Ever held
8
Current + past
New this quarter
2
Exited this quarter
1

Marquee-fund ownership over time

Aug 14, 2024May 14, 2025Feb 12, 2026May 15, 2026
Now
8

This quarter's activity

New positions opened

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Citadel Advisors re-entered$0.00$144—
Two Sigma Investments re-entered$43$144+239%
D.E. Shaw re-entered$43$144+239%
AQR Capital Management$43$144+239%
Renaissance Technologies re-entered$39$144+266%
Millennium Management$39$144+266%
Duquesne Family Office$146$144-1%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Point72 Asset Management 2× in & out→ $146+45%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Revolution Medicines, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
2
Filings · last 90d
19
Total on file
347
Recent SEC buffer
Most recent
May 28, 2026

30d / 90d windows measured from May 28, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 347 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · Revolution Medicines, Inc.

Annual figures sourced directly from Revolution Medicines, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$0
FY2025
Net income
-$1.13B
FY2025-89% YoY
EPS (diluted)
$-5.95
FY2025-66% YoY
Free cash flow(?)
-$913.73M
FY2025-61% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Revolution Medicines, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Duquesne Family OfficeQ2 2026open$146$144-1%
Renaissance TechnologiesQ2 2026open$149$144-3%
Point72 Asset ManagementQ1 2026Q2 2026$101$146+45%
Two Sigma InvestmentsQ4 2025open$68$144+113%
D.E. ShawQ3 2025open$36$144+301%
Millennium ManagementQ2 2025open$39$144+266%
Renaissance TechnologiesQ2 2025Q1 2026$39$97+147%
Citadel AdvisorsQ3 2024Q1 2025$0.00—+0%
Citadel AdvisorsQ3 2024open$43$144+239%
Two Sigma InvestmentsQ3 2024Q1 2025$43$41-4%
D.E. ShawQ3 2024Q2 2025$43$39-7%
D.E. ShawQ3 2024open$0.00—+0%
AQR Capital ManagementQ3 2024open$43$144+239%
Point72 Asset ManagementQ3 2024Q4 2024$43$57+35%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.